OncoMatch/Clinical Trials/NCT07249905

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

Is NCT07249905 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MDX2003 for lymphoma.

Phase 1/2RecruitingModeX Therapeutics, An OPKO Health CompanyNCT07249905Data as of May 2026

Treatment: MDX2003 — This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Biomarker criteria

Required: CD19 positivity (positive)

Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.

Required: CD20 positivity (positive)

Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 2 prior lines

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify